Scientists from WHO suggest that Pfizer’s oral antiviral drug (a combination of nirmatrelvir and ritonavir tablets) is strongly recommended for people with non-severe COVID-19 with a high risk of hospitalization.
The experts explain that nirmatrelvir/ritonavir likely represents a superior choice for these patients.
This is because it may prevent more hospitalizations than the alternatives, has fewer potential harms than the antiviral drug molnupiravir, and is easier to administer than intravenous options such as remdesivir and antibody treatments.
However, they recommend against its use in patients at lower risk, as the benefits are trivial.
And they make no recommendation for patients with severe or critical COVID-19, as there are currently no trial data on nirmatrelvir/ritonavir for this group.
The research is published in The BMJ and was conducted by Arnav Agarwal et al.
The new recommendation is based on new data from two randomized controlled trials involving 3,100 patients.
In these studies, moderate certainty evidence showed that nirmatrelvir/ritonavir reduced hospital admission (84 fewer admissions per 1,000 patients) and high certainty evidence suggested little or no risk of adverse effects leading to drug discontinuation.
WHO also makes a conditional (weak) recommendation to use the antiviral drug remdesivir for patients with non-severe COVID-19 at highest risk of hospitalization.
This is based on new data from five randomized controlled trials involving 2,700 patients and replaces a previous recommendation against treatment with remdesivir in all patients with COVID-19 regardless of disease severity.
The team noted that antiviral drugs should be administered as early as possible in the course of the disease.
The living guidelines allow researchers to update previously vetted and peer reviewed evidence summaries as new information becomes available.
Today’s guidance adds to previous conditional recommendations for the use of molnupiravir for high-risk patients with non-severe COVID-19 and for the use of sotrovimab or casirivimab-imdevimab (monoclonal antibody treatments) in selected patients; and against the use of convalescent plasma, ivermectin and hydroxychloroquine in patients with COVID-19 regardless of disease severity.
For patients with severe COVID-19, WHO strongly recommends corticosteroids, with the addition of IL-6 receptor blockers or baricitinib.
Sign up for our newsletter for more information about this topic.
If you care about COVID, please read studies about link between blood group and severe COVID-19, and many people with COVID-19 get deadly ‘black fungus’ disease.
For more information about COVID, please see recent studies that new air filters could rapidly kill COVID-19, and results showing scientists find persistent immune inflammation after mild COVID-19.
Copyright © 2022 Knowridge Science Report. All rights reserved.
